Fundraising Fox
/Companies
Sign in

Triumvira Immunologics

Austin, US · Founded 2015 · Ontario, Canada corporation · 21 employees on LinkedIn · 10 known investors

Find your way into Triumvira Immunologics

Each arrow is one introduction. Sign up to fill in the first one.

117 people can intro you to JON

Ask Drew Schaal to introduce you to JON IRVIN

You →Drew · together at Bridgepoint Consulting, LLC →JON

83 people can intro you to PAUL

Ask Jamie Chen to introduce you to PAUL LAMMERS, MD, MSc

You →Jamie · together at Decoy Therapeutics Inc. →PAUL

20 people can intro you to TERESA

Ask Sam Okafor to introduce you to TERESA MCROBERTS

You →Sam · together at Columbia Business School →TERESA

Sign up to find every way you can get introduced to Triumvira Immunologics

  • Your email: who you already know at Triumvira Immunologics, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Triumvira Immunologics team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

Triumvira is a clinical-stage immuno-oncology company developing autologous and allogeneic T cell therapeutics for cancer treatment. The company applies T cell biology and targeted immunotherapy approaches to address oncology.

BiotechHealthtechMedical Devices

Founders & leadership

TM
TERESA MCROBERTSChief Financial Officer2021–2023Teresa McRoberts joined Triumvira Immunologics as CFO in early 2021, bringing two decades of healthcare portfolio management and investment banking experience. Her background includes roles in healthcare-focused investing, M&A, capital raising, and financial strategy for biotechnology companies.
PLPAUL LAMMERS, MD, MSc
PAUL LAMMERS, MD, MScChief Executive Officer2018–2024Paul Lammers is a physician and biopharmaceutical executive who has held leadership positions at public and private companies, with therapeutic experience across women's health, men's health, neurodegenerative diseases, metabolic disorders, orphan diseases, and oncology.
JIJON IRVIN
JON IRVINConsultant2023–2024He brings extensive experience in financial management across biotechnology, medical devices, software, and high-technology companies, ranging from early-stage ventures to mature organizations, and has been involved in over $650 million in public and private financings.

Board

DJ
DANIEL JANSEBoard director
JE
JURGEN ECKHARDTBoard director
EW
ELIZABETH WILLIAMSBoard director
WMWIDYA MULYASASMITA
WIDYA MULYASASMITABoard of Directors2022–2023Principal at B Capital Group
BM
BRIAN M. BLOOMBoard director
LC
LEE COOPERBoard director
CC
CYNTHIA COLLINS, MBABoard director
SS
SCOTT SMITHBoard director

Investors · 10

B Capital Grouplisted by B Capital GroupSan Francisco · $10M – $50M

How we know: B Capital Group's portfolio page · a partner's Signal profile · the VCSheet dataset · Not right? Tell us

B4 Capitallisted by B4 Capital$10M – $50M
Checkmate Capital Group LLClisted by Checkmate Capital Group LLCPasadena
Leaps by BayerreportedLeverkusen

How we know: medcitynews.com · Not right? Tell us

Northpond VenturesreportedBethesda · $100K – $5M

How we know: medcitynews.com · Not right? Tell us

Oceanpine CapitalreportedBeijing

How we know: medcitynews.com · Not right? Tell us

Also in the syndicate · 3

Bloom Burton & Co.Centre for Commercialization of Cancer ImmunotherapyViva Biotech Holdings

Funding

SEC filings, press & company announcements

$114.7M disclosed across 2 of 3 rounds · 2020–2022

▶$59.7MraisedSep 2022 · 13 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • CYNTHIA COLLINS, MBADirector
  • SCOTT SMITHDirector
  • DANIEL JANSEDirector
  • JURGEN ECKHARDTDirector
  • TERESA MCROBERTSExecutive Officer
  • PAUL LAMMERS, MD, MScExecutive Officer, Director
  • ELIZABETH WILLIAMSDirector
  • JON IRVINExecutive Officer
  • WIDYA MULYASASMITADirector
  • BRIAN M. BLOOMDirector
  • LEE COOPERDirector
Offering amount
$59.7M
Amount sold
$59.7M
First sale
Apr 2021
Incorporated
Corporation, Ontario, Canada
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does Triumvira Immunologics do?
Triumvira is a clinical-stage immuno-oncology company developing autologous and allogeneic T cell therapeutics for cancer treatment. The company applies T cell biology and targeted immunotherapy approaches to address oncology.
Who are Triumvira Immunologics's investors?
Triumvira Immunologics's investors include ATEM Capital Fund, B Capital Group, B4 Capital, Checkmate Capital Group LLC, Leaps by Bayer, Northpond Ventures, Oceanpine Capital.
How much funding has Triumvira Immunologics raised?
Triumvira Immunologics has disclosed $114.7M raised across 2 of its 3 known rounds.
Where is Triumvira Immunologics headquartered?
Triumvira Immunologics is headquartered in Austin, US.